PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Procept BioRobotics shares soared 30% on Wednesday after the company said its robotic system designed to treat benign prostatic hyperplasia received clearance from the Food and Drug Administration ...

View PROCEPT BioRobotics Corp. PRCT stock quote prices, financial information, real-time forecasts, and company news from CNN.

PROCEPT BioRobotics (NASDAQ:PRCT) is preparing to release its quarterly earnings on Tuesday, 2026-02-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...

Fintel reports that on September 2, 2025, Oppenheimer upgraded their outlook for PROCEPT BioRobotics (NasdaqGM:PRCT) from Perform to Outperform. Analyst Price Forecast Suggests 73.03% Upside As of ...

Waters stated, “We now expect full year 2025 total revenue to be approximately $325.5 million, representing growth of approximately 45% compared to 2024.” System sales guidance for the U.S. remains at ...

On Thursday, Spruce Point Capital released a detailed report on PROCEPT BioRobotics (NASDAQ:PRCT), raising concerns about the claims surrounding its market potential and growth prospects, suggesting ...

META: $214.48 million (5.3% of AUM) GOOGL: $171.23 million (4.2% of AUM) AMZN: $161.25 million (4.0% of AUM) NVDA: $149.51 million (3.7% of AUM) V: $137.50 million (3.4% of AUM) As of October 21, 2025 ...

Shares of PROCEPT BioRobotics (PRCT) fell 8% on Thursday after Leerink Partners downgraded the stock to Market Perform from Outperform and lowered its price target to $29 from $31, citing growing ...